Polyclonal Antibody to Extracellular Signal Regulated Kinase 1 (ERK1)
| Code | Size | Price |
|---|
| PAB357Hu01-20ul | 20ul | £89.00 |
Quantity:
| PAB357Hu01-100ul | 100ul | £169.00 |
Quantity:
| PAB357Hu01-200ul | 200ul | £228.00 |
Quantity:
| PAB357Hu01-1ml | 1ml | £523.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
HS44KDAP; HUMKER1A; P44ERK1; P44MAPK; PRKM3; MAPK3; ERT2; Mitogen-Activated Protein Kinase 3; Insulin-stimulated MAP2 kinase; Microtubule-associated protein 2 kinase
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Extracellular Signal Regulated Kinase 1
Reactivity:
Mu;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blottin:g: 0.01-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://wwwnature.fenshishang.com/articles/s41598-021-02454-1;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Extracellular Signal Regulated Kinase 1 (ERK1) | RPB357Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||